Modeling Science for
Cancer Therapy

These new models recreate clinical situations that require more effective therapies, such as high-risk MM with TP53 loss, genetic instability, or t(4;14), VRD and BCMA-targeted refractory states, extramedullary disease, and light-chain amyloidosis. In parallel, MIMO is generating patient-derived xenograft (PDX) models from MM patient samples engrafted into IL6-secreting immunodeficient mice reconstituted with a human immune system. The goal of the humanized PDX is to directly study clinical immunotherapy agents that cannot be tested in other experimental systems. These new models will be available by Q1-Q2 2025. Additionally, MIMO is expanding the generation of humanized mouse and PDX models for the principal B-cell lymphoma subtypes (DLBCL, FCL, LPL/WM, MZL/MALT lymphoma), as well as for acute myeloid leukemia (AML), which will be sequentially available by Q2-Q3 2025. As proof-of-principle, DLBCL of ABC and GCB subtypes with humanized CD19 or CD20 and CD3ε are being used to evaluate TCE and CAR T-cell therapies, while AML PDXs are serving to test targeted agents and immunotherapy combinations. Our expectation at MIMO is that such optimized, complementary mouse and human platforms will broaden and strengthen research collaborations with pharmaceutical companies for addressing virtually all scientific and clinical issues in hematology/oncology. Now located at the University of Navarra CIMA building, in Q1 2025 MIMO will move to its own state-of-the art research facilities currently under construction within the University of Navarra campus. Close to the Schools of Medicine, Science and Pharmacy, the Clinica University of Navarra hospital and CIMA buildings, MIMO and the University of Navarra have signed a collaboration agreement for the interchange and use of a wide range of services, including multiparametric flow cytometry, cell sorting, high-throughput and single-cell genomics, micro-CT and micro-PET imaging for rodents, surgery, histopathology, toxicology, human tissue bank, and computational data resources. MIMO counts on an international advisory network with key opinion leaders in hematology, oncology and immunology. Our final goal at MIMO is to become the preferred partner of pharmaceutical companies for preclinical research in cancer.